<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212341</url>
  </required_header>
  <id_info>
    <org_study_id>MG4101_P1</org_study_id>
    <nct_id>NCT01212341</nct_id>
  </id_info>
  <brief_title>Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor</brief_title>
  <acronym>MG4101</acronym>
  <official_title>A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who
      underwent leukapheresis. These cells were processed based on a novel method for ex vivo
      activation and expansion using an irradiated and activated autologous feeder cell system.
      MG4101 has anti-tumor activities against various tumors including malignant lymphomas in
      vitro as well as in vivo tumor model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the MTD of allogenetic NK cells</measure>
    <time_frame>4-5 weeks</time_frame>
    <description>DLT is defined as follows:
Any toxicity at grade 3 or over for 5 days or more
All grade 4 toxicities
GVHD at grade 2 or over</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the overall response rate</measure>
    <time_frame>4-5 weeks</time_frame>
    <description>RECIST v1.1 for solid tumor or revised response criteria for malignant lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety</measure>
    <time_frame>4 -5 weeks</time_frame>
    <description>NCI-CTCAE v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of allogeneic NK cells</measure>
    <time_frame>4-5 weeks</time_frame>
    <description>To quantify the persistence of donor NK cells in recipients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Malignant Lymphomas</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Singe-dose infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: 1x10^6 cells/kg Cohort 2: 1x10^7 cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeated dose infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: 1x10^6 cells/kg Cohort 4: 3x10^6 cells/kg Cohort 5: 1x10^7 cells/kg Cohort 6: 3x10^7 cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic NK cells</intervention_name>
    <arm_group_label>Singe-dose infusion</arm_group_label>
    <arm_group_label>Repeated dose infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Histologically or cytologically confirmed malignant lymphoma or solid tumor

          -  After the failure of standard treatment

          -  KPS &gt;70 or ECOG PS 0-2

          -  Adequate bone marrow, renal, and liver functions

          -  Expected survival at least 3 months

          -  Informed consent

        Exclusion Criteria:

          -  Pregnancy or lactating woman

          -  HIV patients

          -  Prior exposure to cell-based therapy

          -  Hypersensitivity to interleukin-2

          -  Patients with autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Tae Min Kim/Assistant Professor</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>Allogenetic NK cells</keyword>
  <keyword>Lymphomas</keyword>
  <keyword>Solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

